Xilinx, Inc. : Welcomed earnings release
Entry price | Target | Stop-loss | Potential |
---|
$45.56 |
$0 |
$43.95 |
-100% |
---|
Xilinx' stock has recently surged after the publication of Q1 2014 earnings. The EPS is up 19% to USD 0.56 (estimate 0.472) and sales are slightly down -0.66% to 579 million dollars (estimate 550 million).
Since mid-July, analysts have sharply revised upward their earnings per share estimates: EPS is expected to reach almost USD 2.5 in 2014 vs USD 2.3 a month ago.
Technically, the security shows a bullish configuration on all time scales. However, the stock has recently been stopped by the USD 47.15 resistance and is heading towards the USD 44.5/45 support. The latter, combined with the 20-day moving average should help prices to reach again USD 47.2.
According to both technical and fundamental elements, it seems opportune to take a long position in case of a comeback on the 20-day moving average (approximately at USD 45). The bullish trend should allow the security to reach the USD 47.15 resistance. If the stock crosses it, a new target price will be set. A stop loss will be placed under the USD 44.5 support to avoid a downtrend.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.